Unlocking The Potential of SRMS as A Drug Target Or Biomarker

Target Name: SRMS

NCBI ID: G6725

SRMS

Unlocking The Potential of SRMS as A Drug Target Or Biomarker

SRMS (Src-related kinase) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and skeletal muscles. It is a member of the Src family of kinases, which are known for their ability to activate tyrosine kinase signaling pathways. In addition to its kinase activity, SRMS also has been shown to have several unique features that make it a potential drug target or biomarker.

One of the key features of SRMS is its lack of C-terminal regulatory tyrosine and N-terminal myristylation sites. These genetic modifications are often associated with the regulation of protein stability and localization, and their absence in SRMS could have implications for the way the protein is processed and degraded. Additionally, the absence of these sites may also impact the ability of SRMS to interact with other proteins, which could further influence its function.

Another feature of SRMS is its ability to induce cell death in certain cell types through the production of reactive oxygen species (ROS). This process, known as apoptosis, is a natural response to harmful stimuli and can be a potential mechanism for targeting diseases that are characterized by uncontrolled cell growth or proliferation. The production of ROS by SRMS may also be relevant to its potential as a drug target, as drugs that can induce apoptosis in cancer cells may be effective in treating this disease.

In addition to its potential as a drug target or biomarker, SRMS also has several potential therapeutic applications. For example, it has been shown to play a role in the regulation of muscle growth and maintenance, which could make it a potential target for drugs that are designed to promote muscle growth or prevent muscle loss. Additionally, SRMS has also been shown to be involved in the regulation of cell adhesion, which could make it a potential target for drugs that are designed to modify cell behavior.

Overall, SRMS is a protein that has several unique features that make it a potential drug target or biomarker. Its lack of C-terminal regulatory tyrosine and N-terminal myristylation sites, as well as its ability to induce cell death through the production of ROS, make it a promising target for drugs that are designed to inhibit uncontrolled cell growth or promote apoptosis. Additionally, its role in the regulation of muscle growth and maintenance could make it a potential target for drugs that are designed to promote muscle growth or prevent muscle loss. Further research is needed to fully understand the unique functions of SRMS and its potential as a drug target or biomarker.

Protein Name: Src-related Kinase Lacking C-terminal Regulatory Tyrosine And N-terminal Myristylation Sites

Functions: Non-receptor tyrosine-protein kinase which phosphorylates DOK1 on tyrosine residues (PubMed:23822091). Also phosphorylates KHDRBS1/SAM68 and VIM on tyrosine residues (PubMed:29496907). Phosphorylation of KHDRBS1 is EGF-dependent (PubMed:29496907)

The "SRMS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SRMS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets